Pandemic 2

Children-the Hague, June 13, 2011-2 doses of AS03 [] [B] vaccine adjuvant antibodies had to receive the levels of protection against the same strain of H1N1 that would be in a second season of influenza, according to the results of the study presented today at the 29th annual meeting of the European society for paediatric infectious diseases (ESPID).
A strengthening of the vaccine against the trivalent seasonal influenza (TIV) a year was very well tolerated and immunogenic, added the Woolf researcher t. Walker, MD, Center for clinical research, Wellcome Trust, University of Southampton and Southampton of the National Institute of health (NIHR) respiratory biomedical research unit, national health, hospitals of the University of Southampton, Southampton service is overtuigdVerenigd Kingdom of the research.
It is also safe to manage TIV in the season after the administration of the pandemic vaccine.
Dr. Walker presented the results of a study that the persistence of antibodies in 13 months post vaccination of children from 6 months to 12 years 2 doses of both AS03 [] [B received]-adjuvant or nonadjuvanted pandemic influenza H1N1 vaccine and antiserum in an earlier study, and in this process, the immunogenicity and reactogenicity of a dose of TIV in this one season vaccinated children evaluated.
323 Children blood samples were taken in 13 months after the last dose in the first process, and the levels of antibodies against the virus of the 2009 H1N1 flu pandemic identified. This group, 302 children received a single dose of TIV and microneutralisation (MN) assessed the immunogenicity day 21.
The assessment of the decline in 13 months at the levels of antibodies in both groups of vaccination; However, had a significant percentage of children who received adjuvant vaccine AS03B-titles for MN in 1: 40 or more in comparison with children who received the vaccine nonadjuvanted.